These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 25139843

  • 1. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR.
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC.
    PLoS One; 2016 Nov; 11(4):e0153696. PubMed ID: 27104951
    [Abstract] [Full Text] [Related]

  • 5. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D.
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [Abstract] [Full Text] [Related]

  • 6. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Sugimoto N, Yamagishi Y, Mikamo H.
    J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
    [Abstract] [Full Text] [Related]

  • 7. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A.
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [Abstract] [Full Text] [Related]

  • 8. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F, Perilli M, Amicosante G, Lombardi G, Belloni R, Zollo A, Bianchi C, Toniolo A.
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [Abstract] [Full Text] [Related]

  • 9. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK, Kim JH, Sohn JW, Yang KS, Kim MJ.
    Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
    Harada Y, Morinaga Y, Kaku N, Nakamura S, Uno N, Hasegawa H, Izumikawa K, Kohno S, Yanagihara K.
    Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
    [Abstract] [Full Text] [Related]

  • 15. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis.
    Kurihara Y, Hitomi S, Oishi T, Kondo T, Ebihara T, Funayama Y, Kawakami Y.
    J Infect Chemother; 2013 Oct; 19(5):799-805. PubMed ID: 23371453
    [Abstract] [Full Text] [Related]

  • 16. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK, Park YJ.
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [Abstract] [Full Text] [Related]

  • 17. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH, Lee NR, Joo EJ, Moon SY, Choi JK, Park DA, Peck KR.
    Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
    Mutnick AH, Turner PJ, Jones RN.
    J Chemother; 2002 Jun; 14(3):253-8. PubMed ID: 12120879
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.